Based in New York City, Aetion (pronounced eh-tee-ahn) is a leading healthcare technology company that delivers the real-world analytics and evidence needed for value-based care. With its patented rapid-cycle analyticsTM technology, the Aetion Evidence Platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in patient care. The company is backed by Flare Capital Partners, Lakestar, Oxeon Ventures and other leading individual health technology investors. Learn more at www.aetion.com.
Aetion has raised a total of $74.6M in funding over 3 rounds. Their latest funding was raised on Feb 5, 2019 from a Series B round.
Aetion has 1 registered patent in the 'Computing; Calculating' category. Additionally, Aetion has registered 2 trademarks with the most popular class being 'Scientific and technological services'.